Comment Tentarix ouvre la voie à de nouvelles approches en immunologie

When Andy Kidd joined Tentarix Biotherapeutics as the company’s new CEO in 2024, it was because he was intrigued by the work the company was doing to solve a problem that had frustrated drug developers for decades. How do you improve the targeting of therapies addressing known biology while also reducing the chance of that therapy causing serious harm everywhere else in the body? For therapeutic developers seeking to maximize the therapeutic window, the answer to this question was effectively the holy grail.

Tentarix develops cell-targeted multispecific antibodies — molecules engineered to do two things at once. One part performs the desired biological action, agonizing or blocking a particular pathway. The other acts as a precision guide, directing that action exclusively to a specific cell type. The result is a therapy that delivers the effect you want, where you want it, without triggering the systemic consequences that have historically made these approaches unworkable.

"The opportunity is to make an antibody that does what we want to help that disease, but only does it on the right type of cell," says Kidd. "So we're able to combat the disease, but without all of the typical side effects and safety concerns."

The problem hiding in plain sight

Tentarix works with well-known biology. It deliberately targets mechanisms that are already well understood — areas where the science is clear but where existing approaches have, until now, been inadequate.

"There are quite a few examples where companies have seen the potential to do something with a particular receptor or pathway and sometimes gotten even as far as the clinic before they realized the magnitude of the systemic side effects," says Kidd. "We've reached a point as an industry where we already have drugs for a lot of the clear, clean-cut targets. The next frontier is to go after this more complex biology."

That gap between the dose required for efficacy and the dose at which safety problems emerge has been the defining limitation of several biological pathways, including cytokine agonism. Tentarix's approach eliminates that gap by directing the biology to the right address.

A vast opportunity hiding in a $2 billion market

Cytokine antagonism has produced some of the best-selling drugs in history, with combined sales from a couple of years ago exceeding $50 billion. Yet at the same time, cytokine agonism (activating cytokines to drive a therapeutic effect) had only generated sales of roughly $2 billion. Much of the difference is explained by systemic toxicity.

"The opportunity to close that gap is vast," says Kidd.

Tentarix is initially focused on autoimmune disease — with a particular emphasis on inflammatory bowel disease, mucosal healing, and fibrosis — and on oncology, targeting solid tumors in patients for whom existing checkpoint inhibitor therapies have not been effective.

But making these molecules work isn't straightforward. To do so, Tentarix has built a four-part platform: to identify the right cell surface protein to target; build molecules using proprietary stabilized human VH-binders; deploy high-throughput functional screening across tens or hundreds of thousands of molecular variants; and deploy a cross-functional team to engineer and optimize these screening hits into viable therapeutics.

"We might find when we screen them for that cell-targeted activity that only 10 to 100 actually have activity," says Kidd. "There's a huge drop off and it's very, very difficult to actually find molecules that have this kind of cell-target dependent activity."

A partner who understood the nuances

By the time Tentarix was ready to look for investors in its Series B round, it had a unique profile. A partnership with Gilead was being finalized, and another with AbbVie was in the works. There were also plans to build an internal pipeline. As such, the team wanted a backer who understood the therapeutic approach and was a company builder who understood how to work with the team to bring this approach to the market.

Amplitude Ventures was the perfect fit. The firm brought deep expertise in antibody biology and a genuine willingness to sit with the nuances of Tentarix's specific situation. "Investors see a lot of companies, they see a lot of pattern recognition, but underneath that there's always nuances and differences," says Kidd. "I really appreciate the way Amplitude listens and takes the time to understand them."

In practical terms, that showed up in ways that mattered. When Tentarix was working through CDMO selection, Amplitude drew on experience from across its portfolio to provide guidance at every stage of the process. The firm HAS ALSO made introductions to other investors, to portfolio companies navigating similar challenges, and to clinicians whose input shaped key strategic decisions. "They do a very good job of leveraging their portfolio and relationships to give us access to people that we need," says Kidd.

The road ahead

Tentarix is currently in the discovery stage, with several programs advancing toward IND-enabling studies. Within roughly the next 12 months, the company is targeting completion of its partnered programs with AbbVie and Gilead while advancing its internal pipeline toward the clinic.

"The potential impact in disease is huge because there are so many areas where we already understand the biology," says Kidd. "What's been holding us back has been the tools — the ability to engineer proteins that are complex enough and nuanced enough to do what we need them to do."

Tentarix believes it now has those tools. And with Amplitude as a partner, it has the backing and the network to put them to work.